The Recall Desk
ModerateFDA (Drugs)·D-0208-2025·Announced 2025-01-29

Venlafaxine Extended-Release Tablets Recalled for Missing Tablet Identification

Appco Pharma LLC is recalling Venlafaxine Extended-Release Tablets, 150mg, due to missing tablet identification imprints. The defect affects 1,380 bottles distributed nationwide.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: FDA Class III recall with no reported illnesses or injuries. The hazard is a manufacturing specification failure—missing tablet identification—classified as a labeling defect rather than a safety hazard with reported harm.

Plain-English summary

Appco Pharma LLC is recalling Venlafaxine Extended-Release Tablets, 150mg (NDC 43598-943-90), Lot #2402101UR, expiration 02/28/2027, due to a manufacturing specification failure. The tablets lack the identification number imprint on either side of the tablet.

The affected product consists of 1,380 bottles distributed nationwide throughout the United States.

The recalled product

Product
VENLAFAXINE (VENLAFAXINE)
Brand
VENLAFAXINE
Manufacturer
Appco Pharma LLC
Category
Drug — Antidepressant
Hazard
  • missing-imprint
  • labeling-defect

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot #: 2402101UR
  • Exp 02/28/2027

UPCs (4)

  • 0343598943909
  • 0343598944906
  • 0343598944302
  • 0343598943305

Distribution

Distributed nationwide across the United States.

Related recalls

Same category